Straits Times Index
3,348.87 +12.28 (+0.37%) S&P 500
5,248.25 -29.26 (-0.55%) Dow
38,300.50 -385.82 (-1.00%) Nasdaq
16,707.02 -28.00 (-0.17%) Bitcoin USD
69,233.88 +1,246.68 (+1.83%) CMC Crypto 200
1,491.34 +23.40 (+1.60%)
CADL Oct 2024 5.000 put
| Previous close | 0.7500 |
| Open | N/A |
| Bid | 0.5500 |
| Ask | 2.8500 |
| Strike | 5.00 |
| Expiry date | 2024-10-18 |
| Day's range | 0.7500 - 0.7500 |
| Contract range | N/A |
| Volume | |
| Open interest | 1 |
GlobeNewswireFDA Grants Orphan Drug Designation for CAN-3110 for the Treatment of Recurrent High-Grade Glioma
FDA Orphan Designation provides CAN-3110 certain developmental financial incentives, with potential for up to 7 years of marketing exclusivity in the United States, if approvedCAN-3110 phase 1b data on the feasibility and safety of multiple doses of CAN-3110 will be featured in poster presentation at 2024 ASCO Annual Meeting NEEDHAM, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on deve
ZacksCandel (CADL) Stock Skyrockets 431% Year to Date: Here's Why
Candel (CADL) surges 431% in the year-to-date period, driven by positive developmental and regulatory updates from the clinical program for CAN-2409 across two different cancer indications.
ZacksCandel (CADL) Reports Upbeat Data From Lung Cancer Study
Candel's (CADL) CAN-2409 prolongs overall survival in a phase II study for treating patients with advanced non-small cell lung cancer who are non-responsive to immune checkpoint inhibitor therapy.
